The coverage with evidence development (CED) policy requires enrollment in an active clinical trial for an adult to be eligible for Medicare coverage of treatment for Alzheimer's disease.
Sue Peschin, MHS
Advertisement
Articles by Sue Peschin, MHS
Medicare’s restrictive coverage policies are denying patients with early Alzheimer's disease access to novel treatments. And private payers are following suit.
Advertisement
Latest Updated Articles
Dear Payers: Drugs for Early Alzheimer's Disease are ‘Worth It’Published: October 7th 2024 | Updated:
- The CMS CED Policy Limits Treatment for Early Alzheimer's Disease: What It Is and How It Works
Published: December 16th 2024 | Updated:
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Education Wholly Inadequate for Physician Associates, According to New Survey Results
2
Timing of Menopausal Hormone Therapy May Impact Biomarkers of Alzheimer Disease
3
Menopause Education Lags in Residency Training Across Primary Care Specialties
4
Treating Hot Flashes May Improve Cognitive Symptoms: Study Author Explains the Connection
5
